Tandem Diabetes Care (TNDM) Free Cash Flow Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 9.23% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -39.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.56% |
| Mar 31, 2026 | 29.59% |
| Dec 31, 2025 | -17.72% |
| Sep 30, 2025 | -29.31% |
| Jun 30, 2025 | -47.68% |
| Mar 31, 2025 | -53.36% |
| Dec 31, 2024 | 13.98% |
| Sep 30, 2024 | -14.24% |
| Jun 30, 2024 | -34.84% |
| Mar 31, 2024 | -33.72% |
| Dec 31, 2023 | -41.00% |
| Sep 30, 2023 | 57.89% |
| Jun 30, 2023 | -38.27% |
| Mar 31, 2023 | 0.30% |
| Dec 31, 2022 | -24.00% |
| Sep 30, 2022 | 31.57% |
| Jun 30, 2022 | 23.79% |
| Mar 31, 2022 | 72.21% |
| Dec 31, 2021 | 4.99% |
| Sep 30, 2021 | 112.85% |